GLP-1 Drugs May Shield the Heart After a Heart Attack

A Hidden Crisis After Heart Attacks

Doctors can now unblock a coronary artery within minutes of a heart attack. Yet for nearly half of all patients, the emergency procedure does not tell the full story. Even after the main artery is reopened, millions of microscopic blood vessels inside the heart muscle remain stubbornly constricted — starving tissue of oxygen and raising the risk of heart failure and death. This poorly understood complication is known as "no-reflow."

A landmark study published on March 3, 2026 in Nature Communications now offers a promising explanation — and a potential solution hiding in plain sight: the same class of drugs already used by millions of people worldwide to manage obesity and type 2 diabetes.

The Surprising Role of Pericytes

Researchers from the University of Bristol and University College London (UCL) identified a previously unknown mechanism by which the hormone GLP-1 (glucagon-like peptide-1) — and the drugs that mimic it, including semaglutide (sold as Ozempic and Wegovy) — protect heart tissue after ischaemia.

The key players are pericytes: tiny cells that wrap around capillaries and regulate their diameter. During a heart attack, pericytes contract and clamp shut these microscopic vessels, blocking the flow of blood even after the main artery has been cleared. The research team found that GLP-1 directly targets pericytes by activating ATP-sensitive potassium channels (KATP channels). When these channels open, the electrical charge inside pericytes shifts, calcium influx drops, and the cells relax — allowing capillaries to dilate and blood to flow again.

When researchers genetically removed these potassium channels from the animals in their experiments, GLP-1 drugs lost their protective effect entirely — confirming the channel's central role in the mechanism.

A Brain-Gut-Heart Signalling Pathway

The study maps out a remarkable three-organ circuit. GLP-1 is released in the gut in response to food, signals through the brain, and then triggers protective effects in the heart. The researchers describe this as a "brain-gut-heart" axis — a discovery that adds a new dimension to how physicians might think about cardiac protection during acute coronary events.

"Our findings highlight the potential for these existing drugs to be repurposed to treat the risk of no-reflow in heart attack patients," the Bristol research team stated in a press release accompanying the publication.

Clinical Promise — and Caveats

The findings, based on animal models, still require human clinical trials before GLP-1 drugs can be routinely administered in cardiac wards. Researchers caution that the timing and efficacy of the brain-gut-heart pathway may differ between species. Nevertheless, the fact that GLP-1 drugs are already approved, widely available, and have well-established safety profiles significantly lowers the barrier to repurposing them.

The no-reflow phenomenon is associated with reduced left ventricular ejection fraction, larger infarct size, and a sharply elevated risk of hospital readmission for heart failure within a year. Any treatment that could address it would represent a meaningful advance in emergency cardiac care.

Beyond Weight Loss

The study adds to a rapidly expanding body of evidence that GLP-1 drugs offer benefits far beyond their original indications. Earlier trials had already shown cardiovascular risk reduction in diabetic and obese patients. The new Nature Communications paper takes this further by identifying a specific, direct cardiac mechanism — one that could be activated acutely, in the hours surrounding a heart attack, rather than over months of metabolic treatment.

For cardiologists, the discovery opens a concrete new therapeutic avenue. For the millions of patients who survive heart attacks each year only to face ongoing microvascular damage, it may eventually mean better outcomes — thanks to a drug originally designed to help people lose weight.